SunTrust Robinson Humphrey Starts ARIAD Pharmaceuticals (ARIA) at Buy
- Wall St. rises amid robust earnings, GDP data
- FBI to review more emails related to Clinton's private email use: letter
- Unusual 11 Mid-Day Movers 10/28: (GRVY) (VRTS) (ITGR) Higher; (OPXA) (SNMX) (STON) Lower
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
SunTrust Robinson Humphrey initiated coverage on ARIAD Pharmaceuticals (NASDAQ: ARIA) with a Buy rating and a price target of $22.00.
Shares of ARIAD Pharmaceuticals closed at $13.59 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stocks with Implied Volatility Movement
- JMP Securities Downgrades ARIAD Pharmaceuticals (ARIA) to Market Perform
- Maxim Group Starts Vuzix Corp. (VUZI) at Buy
Create E-mail Alert Related CategoriesHot New Coverage, New Coverage
Related EntitiesSunTrust Robinson Humphrey
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!